Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 15;40(42):6114–6124. doi: 10.1016/j.vaccine.2022.08.024

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 Published by Elsevier Ltd.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Fig. 5 — Polyethylene glycol (PEG) antibodies in participants selected based on their vaccine associated side effects including delayed onset injection site reactions and severe allergic reaction. Sera from BNT162b2 (A) or mRNA-1273 (B) vaccinees was collected at baseline (n = 28 for A and C, and n = 19 for B and D), 14.5 days (arithmetic mean ± 4.8 SD) after the prime (n = 23 for A and C, and n = 17 for B and D) or 25.2 days (arithmetic mean ± 11.6 SD) after the boost (n = 26 for A and C and n = 17 for B and D), and tested for IgG (A and B), IgM (C and D) or IgE (E and F) antibodies against 20 kDa PEGylated BSA by ELISA. Dotted line represents the limit of detection (LoD) of the assay. Statistically significant differences between post-prime/post-boost vs baseline antibody levels are shown. One-way ANOVA with Tukey’s multiple comparisons test was used to determine statistical significance. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.